Search research articles
Contact Us
Filters
Showing results (41-50 of 50) with videos related to
Page
of 5
Sort By:
You have reached the last page of results.
This site can display upto 50 results.
Oncoimmunology
|
May 10, 2019
Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer
Max Hardy-Werbin, Pedro Rocha, Oriol Arpi, et al.
EJNMMI Research
|
December 17, 2017
Correction to: The relationship between endogenous thymidine concentrations and [<sup>18</sup>F]FLT uptake in a range of preclinical tumour models
Kathrin Heinzmann, Davina Jean Honess, David Yestin Lewis, et al.
EJNMMI Research
|
August 13, 2016
The relationship between endogenous thymidine concentrations and [(18)F]FLT uptake in a range of preclinical tumour models
Kathrin Heinzmann, Davina Jean Honess, David Yestin Lewis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 7, 2020
CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations
Enriqueta Felip, Andrea Ardizzoni, Tudor Ciuleanu, et al.
Trends in Ecology & Evolution
|
June 11, 2020
Horizon Scan of the Belt and Road Initiative
Alice C Hughes, Alex M Lechner, Alexander Chitov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 6, 2023
Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)
Naveen S Vasudev, Gemma Ainsworth, Sarah Brown, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists
|
March 5, 2021
Concise Reporting of Benign Endometrial Biopsies is an Acceptable Alternative to Descriptive Reporting
Divya Kriplani, Ana A Olivar, Nairi Tchrakian, et al.
The Lancet. Oncology
|
February 16, 2023
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial
Janet E Brown, Kara-Louise Royle, Walter Gregory, et al.
Ecancermedicalscience
|
February 26, 2016
An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients
Richard Baird, Ian Banks, David Cameron, et al.
Plos One
|
March 28, 2019
Globally important islands where eradicating invasive mammals will benefit highly threatened vertebrates
Nick D Holmes, Dena R Spatz, Steffen Oppel, et al.
Page
of 5
Search research articles
Search
Showing results (41-50 of 50) with videos related to
Sort By:
Page
of 5
You have reached the last page of results.
This site can display upto 50 results.
Oncoimmunology
|
May 10, 2019
Serum cytokine levels as predictive biomarkers of benefit from ipilimumab in small cell lung cancer
Max Hardy-Werbin, Pedro Rocha, Oriol Arpi, et al.
EJNMMI Research
|
December 17, 2017
Correction to: The relationship between endogenous thymidine concentrations and [<sup>18</sup>F]FLT uptake in a range of preclinical tumour models
Kathrin Heinzmann, Davina Jean Honess, David Yestin Lewis, et al.
EJNMMI Research
|
August 13, 2016
The relationship between endogenous thymidine concentrations and [(18)F]FLT uptake in a range of preclinical tumour models
Kathrin Heinzmann, Davina Jean Honess, David Yestin Lewis, et al.
European Journal of Cancer (Oxford, England : 1990)
|
February 7, 2020
CheckMate 171: A phase 2 trial of nivolumab in patients with previously treated advanced squamous non-small cell lung cancer, including ECOG PS 2 and elderly populations
Enriqueta Felip, Andrea Ardizzoni, Tudor Ciuleanu, et al.
Trends in Ecology & Evolution
|
June 11, 2020
Horizon Scan of the Belt and Road Initiative
Alice C Hughes, Alex M Lechner, Alexander Chitov, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 6, 2023
Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)
Naveen S Vasudev, Gemma Ainsworth, Sarah Brown, et al.
International Journal of Gynecological Pathology : Official Journal of the International Society of Gynecological Pathologists
|
March 5, 2021
Concise Reporting of Benign Endometrial Biopsies is an Acceptable Alternative to Descriptive Reporting
Divya Kriplani, Ana A Olivar, Nairi Tchrakian, et al.
The Lancet. Oncology
|
February 16, 2023
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial
Janet E Brown, Kara-Louise Royle, Walter Gregory, et al.
Ecancermedicalscience
|
February 26, 2016
An Association of Cancer Physicians' strategy for improving services and outcomes for cancer patients
Richard Baird, Ian Banks, David Cameron, et al.
Plos One
|
March 28, 2019
Globally important islands where eradicating invasive mammals will benefit highly threatened vertebrates
Nick D Holmes, Dena R Spatz, Steffen Oppel, et al.
Page
of 5